COMPOSITIONS AND METHODS FOR TREATING CYSTIC FIBROSIS

• US 20100303917A1
• Filed: 05/03/2010
• Published: 12/02/2010
• Est. Priority Date: 10/25/2007
• Status: Abandoned Application

• Current Assignee: Revalesio Corporation
• Original Assignee: Revalesio Corporation
• Inventors: Wood, Anthony B., Archambeau, Gregory J., Watson, Richard L.
• Application Number:
  US12/772,506
• Publication Number:
  US 20100303917A1
• Time in Patent Office: Days
• US Class Current: 424/489
• CPC Class Codes: A61K 33/00 Medicinal preparations containing inorganic active ingredients
• CPC Class Codes: C12N 13/00 Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
• CPC Class Codes: G01N 33/6872 Intracellular protein regulatory factors and their receptors, e.g. including ion channels

Abstract

Provided are electrokinetically-altered fluids (gas-enriched (e.g., oxygen-enriched) electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide, upon contact with a cell, modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for using same in treating cystic fibrosis or a symptom thereof. The electrokinetically-altered fluid compositions and methods include electrokinetically-altered fluids optionally in combination with other therapeutic agents (e.g., antibiotics, albuterol, budesonide, etc.). Particular embodiments comprise use and/or synergy with tobramycin for treating bacterial infection, and use and/or synergy with a bronchiodilator. In certain aspects, the methods comprise regulating intracellular signal transduction by modulation of at least one of cellular membranes, membrane potential, membrane proteins (like, membrane receptors, including but not limited to G protein coupled receptors, and intercellular junctions).

Claims

1. A method for treating cystic fibrosis or a symptom thereof, comprising administering to a subject in need thereof a therapeutically effective amount of an electrokinetically altered aqueous fluid comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures substantially having an average diameter of less than about 100 nanometers and stably configured in the ionic aqueous fluid in an amount sufficient for treating or alleviating cystic fibrosis or at least one symptom thereof.

2. The method of claim 1, wherein the charge-stabilized oxygen-containing nanostructures are stably configured in the ionic aqueous fluid in an amount sufficient to provide, upon contact of a living cell by the fluid, modulation of at least one of cellular membrane potential and cellular membrane conductivity.

3. The method of claim 1, wherein the charge-stabilized oxygen-containing nanostructures are the major charge-stabilized gas-containing nanostructure species in the fluid.

4. The method of claim 1, wherein the percentage of dissolved oxygen molecules present in the fluid as the charge-stabilized oxygen-containing nanostructures is a percentage selected from the group consisting of greater than:

0.01%, 0.1%, 1%, 5%;

10%;

15%;

20%;

25%;

30%;

35%;

40%;

45%;

50%;

55%;

60%;

65%;

70%;

75%;

80%;

85%;

90%; and

95%.

5. The method of claim 1, wherein the total dissolved oxygen is substantially present in the charge-stabilized oxygen-containing nanostructures.

6. The method of claim 1, wherein the charge-stabilized oxygen-containing nanostructures substantially have an average diameter of less than a size selected from the group consisting of:

90 nm;

80 nm;

70 nm;

60 nm;

50 nm;

40 nm;

30 nm;

20 nm;

10 nm; and

less than 5 nm.

7. The method of claim 1, wherein the ionic aqueous solution comprises a saline solution.

8. The method of claim 1, wherein the fluid is superoxygenated.

9. The method of claim 1, wherein the fluid comprises a form of solvated electrons.

10. The method of claim 1, wherein alteration of the electrokinetically altered aqueous fluid comprises exposure of the fluid to hydrodynamically-induced, localized electrokinetic effects.

11. The method of claim 10, wherein, exposure to the localized electrokinetic effects comprises exposure to at least one of voltage pulses and current pulses.

12. The method of claim 10, wherein the exposure of the fluid to hydrodynamically-induced, localized electrokinetic effects, comprises exposure of the fluid to electrokinetic effect-inducing structural features of a device used to generate the fluid.

13. The method of claim 1, wherein said at least one symptom is selected from the group consisting of bronchoconstriction, microbial infection, increased mucus secretion, pain, and decreased airflow.

14. The method of claim 13, wherein said electrokinetically altered aqueous fluid decreases bronchoconstriction.

15. The method of claim 14, further comprising a synergistic or non-synergistic inhibition or reduction in bronchoconstriction by simultaneously or adjunctively treating the subject with another bronchiodilating agent.

16. The method of claim 13 wherein said other bronchiodilator comprises albuterol.

17. The method of claim 1, further comprising simultaneously or adjunctively treating the subject with another anti-inflammatory agent.

18. The method of claim 17, wherein said other anti-inflammatory agent comprises a steroid.

19. The method of claim 18, wherein the steroid comprises a glucocorticoid steroid.

20. The method of claim 19, wherein the glucocorticoid steroid comprises Budesonide or an active derivative thereof.

21. The method of claim 17, wherein the at least one additional anti-inflammatory agent is a TSLP and/or TSLPR antagonist.

22. The method of claim 21, wherein the TSLP and/or TSLPR antagonist is selected from the group consisting of neutralizing antibodies specific for TSLP and the TSLP receptor, soluble TSLP receptor molecules, and TSLP receptor fusion proteins, including TSLPR-immunoglobulin Fc molecules or polypeptides that encode components of more than one receptor chain.

23. The method of claim 1, wherein administration of said electrokinetically altered aqueous fluid reduces microbial infection in the subject.

24. The method of claim 23, wherein said microbial infection comprises infection with Pseudomonas.

25. The method of claim 1, further comprising simultaneously or adjunctively treating the subject with another antibiotic agent.

26. The method of claim 25 wherein said antibiotic is selected from the group consisting of:

tobramycin, including TOBI, amikacin, gentamicin, kanamycin, neomycin, netilmicin, paromomycin, streptomycin, apramycin, azithromycin, cefaclor, ceftazidime, cephalexin, ciprofloxacin, imipenem, ofloxacin, piperacillin, colistin, and anti-microbially active derivatives thereof.

27. The method of claim 26, comprising synergistic inhibition or reduction of microbial infection by simultaneously or adjunctively treating the subject with tobramycin or an anti-microbially active derivative thereof.

28. The method of claim 1, wherein said electrokinetically altered aqueous fluid alters the movement of salts or water into or out of epithelial cells.

29. The method of claim 2, wherein modulation of at least one of cellular membrane potential and cellular membrane conductivity comprises altering cellular membrane structure or function by altering of a conformation, ligand binding activity, or a catalytic activity of a membrane associated protein or constituent.

30. The method of claim 29, wherein the membrane associated protein comprises at least one selected from the group consisting of receptors, transmembrane receptors, ion channel proteins, intracellular attachment proteins, cellular adhesion proteins, integrins, etc.

31. The method of claim 30, wherein the transmembrane receptor comprises a G-Protein Coupled Receptor (GPCR).

32. The method of claim 31, wherein the G-Protein Coupled Receptor (GPCR) interacts with a G protein a subunit.

35. The method of claim 2, wherein modulation of at least one of cellular membrane potential and cellular membrane conductivity comprises modulating whole-cell conductance.

36. The method of claim 35, wherein modulating whole-cell conductance, comprises modulating at least one of a linear or non-linear voltage-dependent contribution of the whole-cell conductance.

37. The method of claim 2, wherein modulation of at least one of cellular membrane potential and cellular membrane conductivity comprises modulation of intracellular signal transduction comprising modulation of a calcium dependant cellular messaging pathway or system.

38. The method of claim 2, wherein modulation of at least one of cellular membrane potential and cellular membrane conductivity comprises modulation of intracellular signal transduction comprising modulation of phospholipase C activity.

39. The method of claim 2, wherein modulation of at least one of cellular membrane potential and cellular membrane conductivity comprises modulation of intracellular signal transduction comprising modulation of adenylate cyclase (AC) activity.

40. The method of claim 2, wherein modulation of at least one of cellular membrane potential and cellular membrane conductivity comprises modulation of intracellular signal transduction associated with at least one condition or symptom selected from the group consisting of bronchoconstriction, microbial infection, increased mucus secretion, pain, and decreased airflow.

41. The method of claim 1, comprising administration to a cell network or layer, and further comprising modulation of an intercellular junction therein.

42. The method of claim 41, wherein the intercellular junction comprises at least one selected from the group consisting of tight junctions, gap junctions, zona adherins and desmasomes.

43. The method of claim 41, wherein the cell network or layer comprises at least one selected from the group consisting of pulmonary epithelium, bronchial epithelium, and intestinal epithelium.

44. The method of claim 1, wherein the electrokinetically altered aqueous fluid comprises oxygen present in an amount of at least 8 ppm, at least 15, ppm, at least 25 ppm, at least 30 ppm, at least 40 ppm, at least 50 ppm, or at least 60 ppm oxygen at atmospheric pressure.

45. The method of claim 1, wherein the amount of oxygen present in charge-stabilized oxygen-containing nanostructures of the electrokinetically-alterd fluid is at least 8 ppm, at least 15, ppm, at least 20 ppm, at least 25 ppm, at least 30 ppm, at least 40 ppm, at least 50 ppm, or at least 60 ppm oxygen at atmospheric pressure.

46. The method of claim 1, wherein the electrokinetically altered aqueous fluid comprises at least one of a form of solvated electrons, and electrokinetically modified or charged oxygen species.

47. The method of claim 46, wherein the form of solvated electrons or electrokinetically modified or charged oxygen species are present in an amount of at least 0.01 ppm, at least 0.1 ppm, at least 0.5 ppm, at least 1 ppm, at least 3 ppm, at least 5 ppm, at least 7 ppm, at least 10 ppm, at least 15 ppm, or at least 20 ppm.

48. The method of claim 46 wherein the electrokinetically altered oxygenated aqueous fluid comprises a form of solvated electrons stabilized by molecular oxygen.

49. The method of claim 2, wherein the ability of the electrokinetically altered fluid to alter modulation of at least one of cellular membrane potential and cellular membrane conductivity persists for at least two, at least three, at least four, at least five, at least 6 months in a closed container (e.g., closed gas-tight container).

50. The method of claim 30, wherein the membrane associated protein comprises at least one of CD193 (CCR3), CD154 (CD40L), CD11B, and CD3.

51. The method of claim 1, wherein treating cystic fibrosis, or at least one symptom thereof, comprises modulation of intracellular NF-κ

B expression and/or activity.

52. The method of claim 1, wherein the electrokinetically altered aqueous fluid modulates localized or cellular levels of nitric oxide at the site of administration.

53. The method of claim 1 wherein the electrokinetically altered aqueous fluid promotes a localized decrease at the site of administration of at least one cytokine selected from the group consisting of:

IL-1 beta, IL-8, TNF-alpha, and TNF-beta.

58. The method of claim 1, wherein treating comprises administration by at least one of topical, inhalation, intranasal, oral and intravenous.

59. The method of claim 1, wherein , the charge-stabilized oxygen-containing nanostructures of the electrokinetically-altered fluid comprise at least one salt or ion from Tables 1 and 2 disclosed herein.

33. The method of claim 33, wherein the G protein a subunit comprises at least one selected from the group consisting of Gα

s , Gα

i , Gα

q , and Gα

12.

34. The method of claim 33, wherein the at least one G protein a subunit is Gα

q.

54. A method of formulating a therapeutic agent suitable for use in treating cystic fibrosis or at least one symptom thereof, comprising:

obtaining a therapeutic agent suitable for use in treating cystic fibrosis or at least one symptom thereof, of a subject; and

combining the therapeutic agent with an amount of an electrokinetically altered aqueous fluid comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures substantially having an average diameter of less than about 100 nanometers and stably configured in the ionic aqueous fluid in an amount sufficient for treating cystic fibrosis or at least one symptom thereof, wherein formulating a therapeutic agent suitable for use in treating cystic fibrosis or at least one symptom thereof is afforded.

55. The method of claim 54, wherein the charge-stabilized oxygen-containing nanostructures are stably configured in the ionic aqueous fluid in an amount sufficient to provide, upon contact of a living cell by the fluid, modulation of at least one of cellular membrane potential and cellular membrane conductivity.

57. A pharmaceutical composition, prepared by the method of claim 54.

56. A pharmaceutical composition, comprising:

a therapeutic agent suitable for use treating cystic fibrosis or at least one symptom thereof, of a subject; and

an amount of an electrokinetically altered aqueous fluid comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures substantially having an average diameter of less than about 100 nanometers and stably configured in the ionic aqueous fluid in an amount sufficient for treating cystic fibrosis or at least one symptom thereof.